Q3 2017 Earnings Estimate for MediWound Ltd. (NASDAQ:MDWD) Issued By Jefferies Group
MediWound Ltd. (NASDAQ:MDWD) – Equities researchers at Jefferies Group dropped their Q3 2017 earnings per share (EPS) estimates for shares of MediWound in a research report issued to clients and investors on Thursday. Jefferies Group analyst R. Denhoy now forecasts that the biopharmaceutical company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of ($0.16). Jefferies Group also issued estimates for MediWound’s FY2017 earnings at ($0.81) EPS, FY2018 earnings at ($0.85) EPS and FY2019 earnings at ($0.84) EPS.
Other equities research analysts have also issued reports about the stock. SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a research report on Monday, June 26th. Aegis reiterated a “buy” rating and issued a $11.00 price objective on shares of MediWound in a research report on Thursday, May 25th. Oppenheimer Holdings, Inc. set a $10.00 price objective on shares of MediWound and gave the stock a “buy” rating in a research report on Monday, May 8th. Finally, Zacks Investment Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $10.19.
Shares of MediWound (MDWD) opened at 6.85 on Monday. The firm’s market capitalization is $150.22 million. The stock has a 50 day moving average of $6.96 and a 200-day moving average of $6.41. MediWound has a 12 month low of $4.25 and a 12 month high of $8.58.
MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.01. The business had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. MediWound’s quarterly revenue was up 93.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.34) earnings per share.
Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in MediWound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 7,900 shares in the last quarter. Wells Fargo & Company MN raised its stake in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Institutional investors and hedge funds own 27.32% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.